Nicotine metabolism and urinary elimination in mouse: in vitro and in vivo

References

• Asikainen A, Tarhanen J, Poso A, Pasanen M, Alhava E, Juvonen RO. Predictive value of comparative molecular field analysis modelling of naphthalene inhibition of human CYP2A6 and mouse CYP2A5 enzymes. Toxicology In Vitro 2003; 17: 449–455
   PubMed Web of Science ®Google Scholar
• Benowitz NL. Pharmacology of nicotine: Addiction and therapeutics. Annual Review of Pharmacology and Toxicology 1996; 36: 597–613
   PubMed Web of Science ®Google Scholar
• Brandange S, Lindblom L. The enzyme ‘aldehyde oxidase’ is an iminium oxidase. Reaction with nicotine delta 1′(5′) iminium ion. Biochemical and Biophysical Research Communications 1979; 91: 991–996
   PubMed Web of Science ®Google Scholar
• Damaj MI, Siu EC, Sellers EM, Tyndale RF, Martin BR. Inhibition of nicotine metabolism by methoxsalen: Pharmacokinetic and pharmacological studies in mice. Journal of Pharmacology and Experimental Therapeutics 2007; 320: 250–257
   PubMedGoogle Scholar
• Ezzati M, Hoorn SV, Rodgers A, Lopez AD, Mathers CD, Murray CJ. Comparative Risk Assessment Collaborating Group. Estimates of global and regional potential health gains from reducing multiple major risk factors. Lancet 2003; 362: 271–280
   PubMed Web of Science ®Google Scholar
• Frieling H, Bleich S. Tranylcypromine: New perspectives on an ‘old’ drug. European Archives of Psychiatry and Clinical Neuroscience 2006; 256: 268–273
   PubMedGoogle Scholar
• George TP, O’Malley SS. Current pharmacological treatments for nicotine dependence. Trends in Pharmacological Sciences 2004; 25: 42–48
   PubMed Web of Science ®Google Scholar
• Honkakoski P, Negishi M. The structure, function and regulation of cytochrome P450 2A enzymes. Drug Metabolism Reviews 1997; 29: 977–996
   PubMed Web of Science ®Google Scholar
• Hukkanen J, Jacob P, Benowitz NL. Metabolism and disposition kinetics of nicotine. Pharmacological Reviews 2005; 57: 79–115
   PubMed Web of Science ®Google Scholar
• Juvonen RO, Gynther J, Pasanen M, Alhava E. Pronounced differences in inhibition potency of lactone and non-lactone compounds for mouse and human coumarin 7-hydroxylases. Xenobiotica 2000; 1: 81–92
   Google Scholar
• Juvonen RO, Kaipainen PK, Lang MA. Selective induction of coumarin 7-hydroxylase by pyrazole in D2 mice. European Journal of Biochemistry 1985; 152: 3–8
   PubMedGoogle Scholar
• Kamataki T, Fujieda M, Kiyotani K, Iwano S, Kunitoh H. Genetic polymorphism of CYP2A6 as one of the potential determinants of tobacco-related cancer risk. Biochemical and Biophysical Research Communications 2005; 338: 306–310
   PubMedGoogle Scholar
• Lang MA, Gielen JE, Nebert DW. Genetic evidence for many unique liver microsomal P-450 mediated monooxygenase activities in heterogenic stock mice. Journal of Biological Chemistry 1981; 256: 12068–12075
   PubMed Web of Science ®Google Scholar
• Mäenpää J, Juvonen R, Raunio H, Rautio A, Pelkonen O. Metabolic interactions of methoxsalen and coumarin in humans and mice. Biochemical Pharmacology 1994; 48: 1363–1369
   PubMed Web of Science ®Google Scholar
• Mäenpää J, Sigusch H, Raunio H, Syngelmä T, Vuorela P, Vuorela H, Pelkonen O. Differential inhibition of coumarin 7-hydroxylase activity in mouse and human liver microsomes. Biochemical Pharmacology 1993; 45: 1035–1042
   PubMed Web of Science ®Google Scholar
• Malaiyandi V, Sellers EM, Tyndale RF. Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence. Clinical Pharmacology and Therapeutics 2005; 77: 145–158
   PubMed Web of Science ®Google Scholar
• McNeely W, Goa KL. 5-Methoxypsoralen. A review of its effects in psoriasis and vitiligo. Drugs 1998; 56: 667–690
   PubMed Web of Science ®Google Scholar
• Messina ES, Tyndale RF, Sellers EM. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. Journal of Pharmacology and Experimental Therapeutics 1997; 282: 1608–1614
   PubMed Web of Science ®Google Scholar
• Murphy SE, Raulinaitis V, Brown KM. Nicotine 5′-oxidation and methyl oxidation by P450 2A enzymes. Drug Metabolism and Disposition 2005; 33: 1188–1173
   Google Scholar
• Nakajima M, Yamamoto T, Nunoy K, Yokoi T, Nagashima K, Inoue K, Funae Y, Shimada N, Kamataki T, Kuroiwa Y. Characterization of CYP2A6 involved in 3′-hydroxylation of cotinine in human liver microsomes. Journal of Pharmacology and Experimental Therapy 1996; 277: 1010–1015
   PubMed Web of Science ®Google Scholar
• Oscarson M. Genetic polymorphism in the cytochrome P450 2A6 (CYP2A6) gene: Implications for interindividual differences in nicotine metabolism. Drug Metabolism and Disposition 2001; 29: 91–95
   PubMed Web of Science ®Google Scholar
• Pelkonen O, Mäenpää J, Taavitsainen P, Rautio A, Raunio H. Inhibition and induction of human P450 (CYP) enzymes. Xenobiotica 1998; 28: 1203–1253
   PubMed Web of Science ®Google Scholar
• Pelkonen O, Rautio A, Raunio H, Pasanen M. CYP2A6: A human coumarin 7-hydroxylase. Toxicology 2000; 144: 139–147
   PubMed Web of Science ®Google Scholar
• Poso A, Gynther J, Juvonen RO. A comparative molecular field analysis of cytochrome P450 2A5 and 2A6 inhibitors. Journal of Computer Aided Molecular Design 2001; 15: 195–202
   PubMed Web of Science ®Google Scholar
• Poso A, Juvonen R, Gynther J. Comparative molecular field analysis of compounds with CYP2A5 binding affinity. Quantitative Structure–Activity Relationship 1995; 14: 507–511
   Google Scholar
• Rahnasto M, Raunio H, Poso A, Juvonen R. More potent inhibition of human CYP2A6 than mouse CYP2A5 enzyme activities by derivatives of phenylethylamine and benzaldehyde. Xenobiotica 2003; 33: 529–539
   PubMed Web of Science ®Google Scholar
• Rahnasto M, Raunio H, Poso A, Wittekindt C, Juvonen RO. Quantitative structure–activity relationship analysis of inhibitors of the nicotine metabolizing CYP2A6 enzyme. Journal of Medicinal Chemistry 2005; 48: 440–449
   PubMed Web of Science ®Google Scholar
• Raunio H, Juvonen R, Pasanen M, Pelkonen O, Pääkkö P, Soini Y. Cytochrome P4502A6 (CYP2A6) expression in human hepatocellular carcinoma. Hepatology 1998; 27: 427–432
   PubMed Web of Science ®Google Scholar
• Raunio H, Rautio A, Gullsten H, Pelkonen O. Polymorphisms of CYP2A6 and its practical consequences. British Journal of Clinical Pharmacology 2001; 52: 357–363
   PubMed Web of Science ®Google Scholar
• Sellers EM, Kaplan HL, Tyndale RF. Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking. Clinical Pharmacology and Therapeutics 2000; 68: 35–43
   PubMed Web of Science ®Google Scholar
• Sellers EM, Tyndale RF. Mimicking gene defects to treat drug dependence. Annals of the New York Academy of Sciences 2000; 909: 233–246
   PubMed Web of Science ®Google Scholar
• Sellers EM, Tyndale RF, Fernandes LC. Decreasing smoking behaviour and risk through CYP2A6 inhibition. Drug Discovery Today 2003; 8: 487–493
   PubMed Web of Science ®Google Scholar
• Siu ECK, Tyndale RF. Characterization and comparison of nicotine and cotinine metabolism in vitro and in vitro in DBA/2 and C57BL/6 mice. Molecular Pharmacology 2007; 71: 826–834
   PubMed Web of Science ®Google Scholar
• Siu ECK, Wildenauer DB, Tyndale RF. Nicotine self-administration in mice is associated with rates of nicotine inactivation by CYP2A5. Psychopharmacology 2006; 184: 401–408
   PubMed Web of Science ®Google Scholar
• Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC. Measurement of protein using bicinchoninic acid. Analytical Biochemistry 1985; 150: 76–85
   PubMed Web of Science ®Google Scholar
• Su T, Ding X. Regulation of the cytochrome P450 2A genes. Toxicology and Applied Pharmacology 2004; 199: 285–294
   PubMed Web of Science ®Google Scholar
• Taavitsainen P, Juvonen R, Pelkonen O. In vitro inhibition of cytochrome P450 enzymes in human liver microsomes by a potent CYP2A6 inhibitor, tranyl-2phenylcyclopropylamine (tranylcypromine), and its nonamine analog, cyclopropylbenzene. Drug Metabolism and Disposition 2001; 29: 217–222
   PubMed Web of Science ®Google Scholar
• Tyndale RF, Sellers EM. Variable CYP2A6-mediated metabolism alters smoking behaviour and risk. Drug Metabolism and Disposition 2001; 29: 548–552
   PubMed Web of Science ®Google Scholar
• Wood AW, Conney AH. Genetic variation in coumarin hydroxylase activity in the mouse (Mus musculus). Science 1974; 185: 612–614
   PubMed Web of Science ®Google Scholar
• Zhang W, Kilicarslan T, Tyndale RF, Sellers EM. Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro. Drug Metabolism and Disposition 2001; 29: 897–902
   PubMed Web of Science ®Google Scholar